OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED

Clinical trials for OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED explained in plain language.

Never miss a new study

Get alerted when new OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED trials appear

Sign up with your email to follow new studies for OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

New pill targets genetic flaw in aggressive brain cancers

Disease control Recruiting now

This study is testing an oral drug called safusidenib for adults with specific types of brain tumors that have a genetic change called an IDH1 mutation. The main goal is to see if the drug can safely control the tumor and delay its growth or return after standard treatments. The …

Matched conditions: OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED

Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED

Get alerted when new OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED trials appear

New pill targets genetic flaw in aggressive brain cancers